New CEO Boorady Explains TearScience’s Strategic Shift
TearScience, the device company focused on the role of the meibomian glands in dry eye, has pivoted its business model to concentrate more on early-stage meibomian gland dysfunction (MGD) with the LipiFlow thermal pulsation device and high-definition imaging of the meibomian glands.
00:39 – When did you join TearScience and what changes did you make?
1:16 – How successful is the diagnosis of MGD.
2:00 – The LipiFlow is “really revolutionary.”
2:53 – What changes have you made to the business model?
3:20 – The release of the LipiScan.
4:00 – What percentage of sales is going to optometrists?
4:23 – Can LipiScan be used in regular eye exams?
4:49 – What percentage of Dry Eye patients have MGD?
5:25 – What results are you seeing?
5:50 – Tell us about your latest round.
Joe Boorady serves as President and CEO of TearScience and has spent over 20 years in the ophthalmic industry as an executive. Most recently Dr. Boorady held the role of Senior Vice President of Sales, Service and Marketing for the U.S. at Carl Zeiss Meditec, Inc.